December 16, 2025 - Change of Behavioral Health Services Vendor Reminder On October 16, 2025, we notified you about an important update to our Behavioral Health Services vendor
The FDA has documented more than 1,400 adverse events associated with compounded GLP-1 products
423 GLP-1RAs and AD AD is a progressive and irreversible neurodegenerative disorder characterized by an unclear etiology and pathogenesis
And although by law they must contain the same active ingredient as the drug they mimic, these orally formulated medications may not work nearly as well as the injectable drugs
Furthermore, they has been shown to improve blood sugar and blood pressure levels, making it a great option for those with obesity-related health concerns
If you are having any side effects, that means that the dose is too high